CD8A As a Prognostic and Immunotherapy Predictive Biomarker Can Be Evaluated by MRI Radiomics Features in Bladder Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Oct 14

PMID 36230788

Authors

Zongtai Zheng

Yadong Guo

Xiongsheng Huang

Ji Liu

Ruiliang Wang

Xiaofu Qiu

Shenghua Liu

Affiliations

Soon will be listed here.

Abstract

As an important member of T cytotoxic pathway-related genes, CD8a molecule (CD8A) may be a useful biomarker of immunotherapeutic response and immune cell infiltration. We aimed to investigate the clinical predictive value of CD8A in prognosis and tumor microenvironment (TME) and preoperatively predict the expression of CD8A using radiogenomics in bladder cancer (BCa). Among 12 T cytotoxic pathway-related genes, CD8A was a novel protective gene and had the highest correlations with T cells and Macrophages M1 in BCa. In advanced cancer patients treated with immunotherapy, low CD8A expression was associated with immunotherapeutic failure and poor survival outcomes. CD8A expression was highly related to tumor mutation burden, critical immune checkpoint genes and several types of tumor-infiltrating immune cells, predicting effective response to immunotherapy. The preoperative MRI radiomics features and RNA-sequence data of 111 BCa samples were used to develop a radiomics signature that achieved good performance in the prediction of CD8A expression in both the training (area under curve (AUC): 0.857) and validation sets (AUC: 0.844). CD8A is a novel indicator for predicting the prognosis and immunotherapeutic response in BCa. A radiomics signature has the potential to preoperatively predict the expression of CD8A in BCa patients.

Citing Articles

Construction of a radiogenomic signature based on endoplasmic reticulum stress for predicting prognosis and systemic combination therapy response in hepatocellular carcinoma.

Wu H, Cao S, Xu Z, Wang T, Ji G, Wang K BMC Cancer. 2025; 25(1):131.

PMID: 39849389 PMC: 11756198. DOI: 10.1186/s12885-025-13433-4.

T cell receptor signaling pathway subgroups and construction of a novel prognostic model in osteosarcoma.

Xu H, Tao H Heliyon. 2025; 11(1):e41191.

PMID: 39811323 PMC: 11732464. DOI: 10.1016/j.heliyon.2024.e41191.

Identifying potential drug targets for myocardial infarction through Mendelian randomization.

Yu X, Liu S PLoS One. 2024; 19(12):e0313770.

PMID: 39715222 PMC: 11665999. DOI: 10.1371/journal.pone.0313770.

From Images to Genes: Radiogenomics Based on Artificial Intelligence to Achieve Non-Invasive Precision Medicine in Cancer Patients.

Guo Y, Li T, Gong B, Hu Y, Wang S, Yang L Adv Sci (Weinh). 2024; 12(2):e2408069.

PMID: 39535476 PMC: 11727298. DOI: 10.1002/advs.202408069.

Landscape of the immune infiltration and identification of molecular diagnostic markers associated with immune cells in patients with kidney transplantation.

Xu Z, Sun X, Ma X, Tao B, Wu J, He Y Sci Rep. 2024; 14(1):24770.

PMID: 39433868 PMC: 11493967. DOI: 10.1038/s41598-024-75052-6.

References

Zeng D, Ye Z, Wu J, Zhou R, Fan X, Wang G . Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer. Theranostics. 2020; 10(15):7002-7014. PMC: 7295060. DOI: 10.7150/thno.46176. View

Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C . Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013; 37(3):219-25. DOI: 10.1016/j.canep.2013.02.002. View

Pecoraro M, Takeuchi M, Vargas H, Muglia V, Cipollari S, Catalano C . Overview of VI-RADS in Bladder Cancer. AJR Am J Roentgenol. 2020; 214(6):1259-1268. DOI: 10.2214/AJR.20.22763. View

Ge L, Chen Y, Yan C, Zhao P, Zhang P, A R . Study Progress of Radiomics With Machine Learning for Precision Medicine in Bladder Cancer Management. Front Oncol. 2019; 9:1296. PMC: 6892826. DOI: 10.3389/fonc.2019.01296. View

Jansen C, Prokhnevska N, Master V, Sanda M, Carlisle J, Bilen M . An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019; 576(7787):465-470. PMC: 7108171. DOI: 10.1038/s41586-019-1836-5. View

Bhattacharjee S, Kim C, Park H, Prakash D, Madusanka N, Cho N . Multi-Features Classification of Prostate Carcinoma Observed in Histological Sections: Analysis of Wavelet-Based Texture and Colour Features. Cancers (Basel). 2019; 11(12). PMC: 6966617. DOI: 10.3390/cancers11121937. View

Sanli O, Dobruch J, Knowles M, Burger M, Alemozaffar M, Nielsen M . Bladder cancer. Nat Rev Dis Primers. 2017; 3:17022. DOI: 10.1038/nrdp.2017.22. View

Katz H, Wassie E, Alsharedi M . Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer. Med Oncol. 2017; 34(10):170. DOI: 10.1007/s12032-017-1029-8. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Zheng Z, Xu F, Gu Z, Yan Y, Xu T, Liu S . Combining Multiparametric MRI Radiomics Signature With the Vesical Imaging-Reporting and Data System (VI-RADS) Score to Preoperatively Differentiate Muscle Invasion of Bladder Cancer. Front Oncol. 2021; 11:619893. PMC: 8155615. DOI: 10.3389/fonc.2021.619893. View

11.

Prat A, Navarro A, Pare L, Reguart N, Galvan P, Pascual T . Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Res. 2017; 77(13):3540-3550. DOI: 10.1158/0008-5472.CAN-16-3556. View

12.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

13.

Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

14.

Giraldo N, Sanchez-Salas R, Peske J, Vano Y, Becht E, Petitprez F . The clinical role of the TME in solid cancer. Br J Cancer. 2018; 120(1):45-53. PMC: 6325164. DOI: 10.1038/s41416-018-0327-z. View

15.

Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W . Bladder cancer. Lancet. 2016; 388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. View

16.

Rouanne M, Roumiguie M, Houede N, Masson-Lecomte A, Colin P, Pignot G . Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. World J Urol. 2018; 36(11):1727-1740. DOI: 10.1007/s00345-018-2332-5. View

17.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

18.

Zheng Z, Mao S, Zhang W, Liu J, Li C, Wang R . Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer. Front Oncol. 2021; 10:542492. PMC: 7773013. DOI: 10.3389/fonc.2020.542492. View

19.

Li X, Huang C, Liu Z, Jiang L, Chen J, Xie D . Prognostic Role of the Immunoscore for Patients with Urothelial Carcinoma of the Bladder Who Underwent Radical Cystectomy. Ann Surg Oncol. 2019; 26(12):4148-4156. DOI: 10.1245/s10434-019-07529-y. View

20.

Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S . Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2018; 2(4):230-243. PMC: 5829945. DOI: 10.1136/svn-2017-000101. View